Clinical trials
Solid Tumor (Excluding CNS) clinical trials
Below are recruiting solid tumor (excluding cns) clinical trials, each written for real people, not researchers. We’re tracking 209 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06500819RecruitingPhase 1
B7-H3 CAR T cells for relapsed solid tumors
This trial tests a new immune therapy using your own cells (called B7-H3 CAR T cells) to treat solid tumors that haven't responded to other treatments. It may help children and young adults with certain cancers that are hard to cure.
Palo Alto, CaliforniaAges 2–30 - NCT06385925RecruitingPhase 1/Phase 2
Study of TSN1611 for cancers with KRAS G12D mutation
This trial tests a new drug called TSN1611 for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug can shrink tumors or stop them from growing.
Houston, TexasAges 18–75 - NCT06006169RecruitingPhase 2
Study of new drugs for head and neck cancer and other solid tumors
This trial tests two new drugs, BL-B01D1 and SI-B003, alone or together, for people with head and neck squamous cell carcinoma that has come back or spread. It may also include other solid tumors. The goal is to see if these drugs can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04962867RecruitingPhase 2
Targeting FGFR changes in advanced, hard-to-treat cancers
This Phase 2 study tests a treatment aimed at specific FGFR (a cancer-growth signal) changes found in your tumor. It may help people whose cancer has spread, cannot be removed, or has stopped responding to standard treatment.
Chuo-ku, Tokyo, JapanAges 20 years+ - NCT04954599RecruitingPhase 1/Phase 2
CP-506 for hard-to-treat cancers with DNA repair defects
This Phase 1/2 study tests CP-506 in people with advanced solid tumors that have specific DNA repair problems (homologous recombination or Fanconi anemia-related defects). It may be used alone or combined with carboplatin or an immune therapy, aiming to shrink tumors or improve control when standard options are limited.
BrusselsAges 18 years+ - NCT05512208RecruitingPhase 2
Avutometinib plus defactinib for RAS or BRAF mutated gynecologic cancer
This Phase 2 trial tests a two-drug treatment (avutometinib plus defactinib) for certain advanced gynecologic cancers that have specific cancer-driving DNA changes (like RAS or BRAF). It’s designed for people whose cancer has returned or gotten worse after at least one prior treatment for metastatic disease.
Orlando, FloridaAges 18–99 - NCT05985655RecruitingPhase 1/Phase 2
Study of GTAEXS617 for advanced solid tumors
This trial tests a new drug called GTAEXS617 for adults with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT05948865RecruitingPhase 1
Early trial drug for advanced solid tumors
This Phase 1 study tests CPO301 in adults with advanced or metastatic solid tumors that have worsened or cannot be treated with standard options. It aims to find the safest dose and understand how the treatment affects tumors, especially in certain lung cancer groups.
Los Angeles, CaliforniaAges 18 years+ - NCT05267626RecruitingPhase 1/Phase 2
AU-007 antibody for hard-to-remove or spread skin and lung cancers
This trial tests AU-007, an antibody that targets the IL-2 pathway, in people with certain advanced skin (melanoma) or lung (NSCLC) cancers. It’s designed for cancers that have already progressed after prior immune and other treatments, to see if AU-007 can shrink tumors or control disease.
Miami, FloridaAges 18 years+ - NCT05120596RecruitingPhase 1/Phase 2
Testing an immune-targeting drug by direct injection into tumors
This Phase 1/2 trial tests T3P, a new treatment given directly into reachable solid tumors, to see if it is safe and can help shrink tumors. It is for adults with advanced cancers when no curative treatment is available.
Pamplona, NavarreAges 18–74 - NCT04969315RecruitingPhase 1/Phase 2
Study of two new drugs for advanced kidney, prostate, lung, or mesothelioma cancer
This study tests two new study drugs (TT-4 and TT-10) alone and together in people with certain advanced cancers that have not responded to standard treatments. The goal is to see if these drugs are safe and effective in shrinking tumors or slowing the cancer's growth.
Los Angeles, CaliforniaAges 18 years+ - NCT04895709RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
Clovis, CaliforniaAges 18 years+ - NCT04390737RecruitingPhase 1/Phase 2
Study drug HH2853 for hard-to-treat lymphoma and solid cancers
This Phase 1/2 trial tests the safety and early effectiveness of HH2853 in people whose cancer has come back or did not respond to prior treatment. It may help shrink tumors and guide future treatment for specific cancer types and genetic changes.
Phoenix, ArizonaAges 18 years+ - NCT03715933RecruitingPhase 1
Test drug INBRX-109 for advanced or metastatic solid tumors
This Phase 1 trial tests INBRX-109, a cancer-targeting drug, in people whose solid cancers are locally advanced or spread to other parts of the body. Because it’s Phase 1, the main goal is to see whether it’s safe and how well it can work for different tumor types that meet specific requirements.
Scottsdale, ArizonaAges 12–85 - NCT03310879RecruitingPhase 2
Abemaciclib for advanced tumors with cyclin or CDK4/6 gene changes
This Phase 2 study tests abemaciclib, a targeted cancer medicine, in people with advanced solid tumors that have specific gene changes related to cyclin D or CDK4/6. The goal is to see how well it controls tumors when standard treatments don’t work or aren’t available.
Boston, MassachusettsAges 18 years+ - NCT07644650RecruitingPhase 1
Study of MST-168 for advanced solid tumors
This study tests a new drug called MST-168 for people with advanced solid tumors (cancers that have spread or can't be removed). It aims to find out if the drug is safe and effective, and how the body handles it, which could lead to a new treatment option for those who have run out of standard options.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05687110RecruitingPhase 1
Testing novobiocin for tumors with DNA repair gene changes
This Phase 1 study tests whether novobiocin is safe and finds the best dose for people whose tumors have specific DNA repair gene mutations. It may help if your cancer is hard to treat with standard options, including certain patients who already tried PARP inhibitors.
Duarte, CaliforniaAges 18 years+
Hear when a new Solid Tumor (Excluding CNS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for solid tumor (excluding cns)?
- Yes. Clin2 currently lists 209 recruiting solid tumor (excluding cns) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a solid tumor (excluding cns) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a solid tumor (excluding cns) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.